Neo-Cytamen (Hydroxocobalamin Chloride)

Hydroxocobalamin, the active ingredient in Neo-Cytamen, is a Vitamin B12 (cobalamin) presented as an injectable solution for intramuscular use. It treats vitamin B12 deficiency, pernicious anemia, and cyanide poisoning in patients requiring parenteral supplementation. It is indicated for individuals with impaired absorption of oral vitamin B12, such as those with gastrointestinal disorders or after bariatric surgery.

GNH USA supplies Neo-Cytamen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards, offers regulatory assistance, and ensures reliable logistics for global distribution of this injectable vitamin B12 product.

Neo-Cytamen is used to correct vitamin B12 deficiency and related disorders by providing the active cobalamin needed for normal hematologic and neurologic function.

- Vitamin B12 deficiency: restores normal red blood cell production and neurological health. - Pernicious anemia: compensates for intrinsic factor deficiency, improving hematologic parameters. - Cyanide poisoning: binds cyanide ions to form cyanocobalamin, facilitating detoxification.

Intramuscular hydroxocobalamin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or soreness at the injection site. - Redness or swelling: localized erythema or edema. - Headache: transient headache following administration. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Hypotension: sudden drop in blood pressure. - Thrombophlebitis: inflammation of a vein with clot formation. - Severe skin rash: widespread urticaria or exfoliative dermatitis.

When prescribing Neo‑Cytamen, clinicians should consider several safety measures to minimize risk. - Assess B12 status: confirm deficiency or indication before administration. - Monitor for allergic reactions: observe patient after injection for signs of hypersensitivity. - Use caution in renal impairment: adjust monitoring as hydroxocobalamin is renally excreted. - Avoid concurrent intramuscular injections at same site: reduce tissue irritation. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Hydroxocobalamin can influence the activity of certain drugs, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Metformin: may mask B12 deficiency, necessitating regular monitoring. - Nitrous oxide anesthesia: can inactivate cobalamin, reducing efficacy of hydroxocobalamin therapy. - Chemotherapeutic agents (e.g., methotrexate): high‑dose vitamin B12 may interfere with drug action.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: reduce gastric acidity, potentially decreasing oral B12 absorption (relevant for overall B12 status). - Anticonvulsants (phenytoin, carbamazepine): may increase B12 metabolism, requiring periodic level checks. - Folate supplements: high folate can mask hematologic signs of B12 deficiency, necessitating combined monitoring.